News

• September 1, 2010

  Theratechnologies is pleased to announce the appointment of a new President and CEO More...

• August 2, 2010

  Theratechnologies to present at both BMO and Canaccord Genuity Conferences More...

• July 26, 2010

  Theratechnologies receives a motion of authorization to institute a class action More...

• July 20, 2010

  Update on timeline for FDA Action Date for Theratechnologies’ tesamorelin New Drug Application More...

• July 7, 2010

  Second Quarter 2010: Theratechnologies Reports Lower Burn Rate and Good Financial Position More...

• June 29, 2010

  Theratechnologies added to the Russell Global Index More...

• June 24, 2010

  Theratechnologies Announces Publication of Combined Tesamorelin Phase 3 Results in JCEM More...

• June 8, 2010

  Theratechnologies to present at both Jefferies and Needham conferences More...

• June 2, 2010

  Yves Rosconi, President & CEO of Theratechnologies, will retire on December 31, 2010 More...

• May 27, 2010

  Theratechnologies announces positive vote by FDA Advisory Committee for tesamorelin More...

• April 5, 2010

  Theratechnologies to present at BioFinance 2010 conference More...

• March 25, 2010

  Theratechnologies reports positive outcome at its annual and special meeting of shareholders More...

• March 23, 2010

  Theratechnologies announces financial results for the first quarter 2010 More...

• March 22, 2010

  Theratechnologies: Annual and Special Meeting of Shareholders More...

• March 22, 2010

  FDA Confirms Date for Advisory Committee Review of the Tesamorelin New Drug Application More...

• March 1, 2010

  Theratechnologies Announces Publication of Second Phase 3 Results in JAIDS More...

• February 25, 2010

  Theratechnologies announces a tentative new date for the FDA Advisory Committee review of the tesamorelin New Drug Application More...

• February 10, 2010

  Milestones met in 2009 lead to optimistic outlook for Theratechnologies More...

• February 10, 2010

  Theratechnologies adopts shareholder rights plan More...

• January 25, 2010

  Theratechnologies reports that the FDA will reschedule for administrative reasons the Advisory Committee meeting to review tesamorelin’s NDA More...

• January 18, 2010

  Theratechnologies reports date for FDA Advisory Committee Review of the Tesamorelin New Drug Application More...

• January 11, 2010

  Theratechnologies to present at Biotech Showcase 2010 More...